BR112012012529B1 - Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos - Google Patents

Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos Download PDF

Info

Publication number
BR112012012529B1
BR112012012529B1 BR112012012529-0A BR112012012529A BR112012012529B1 BR 112012012529 B1 BR112012012529 B1 BR 112012012529B1 BR 112012012529 A BR112012012529 A BR 112012012529A BR 112012012529 B1 BR112012012529 B1 BR 112012012529B1
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
compound
substituents selected
alkoxy
Prior art date
Application number
BR112012012529-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012012529A2 (pt
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki MASUO
Motoya SUZUKI
Michihide MAEKAWA
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BR112012012529A2 publication Critical patent/BR112012012529A2/pt
Publication of BR112012012529B1 publication Critical patent/BR112012012529B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012012529-0A 2009-11-25 2010-11-25 Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos BR112012012529B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
JP2009-268040 2009-11-25
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
BR112012012529A2 BR112012012529A2 (pt) 2016-05-03
BR112012012529B1 true BR112012012529B1 (pt) 2021-10-26

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012529-0A BR112012012529B1 (pt) 2009-11-25 2010-11-25 Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos

Country Status (31)

Country Link
US (6) US8299070B2 (enExample)
EP (3) EP3059234A1 (enExample)
JP (6) JP5734628B2 (enExample)
KR (1) KR101766502B1 (enExample)
CN (1) CN102712624B (enExample)
AR (1) AR079164A1 (enExample)
AU (1) AU2010323579C1 (enExample)
BR (1) BR112012012529B1 (enExample)
CA (1) CA2781660C (enExample)
CL (1) CL2012001328A1 (enExample)
CO (1) CO6541645A2 (enExample)
CY (1) CY1117559T1 (enExample)
DK (1) DK2505586T3 (enExample)
ES (1) ES2572935T3 (enExample)
HR (1) HRP20160579T1 (enExample)
HU (1) HUE028016T2 (enExample)
IL (1) IL220009A (enExample)
ME (1) ME02447B (enExample)
MX (1) MX2012006017A (enExample)
MY (1) MY161095A (enExample)
NZ (1) NZ600840A (enExample)
PE (1) PE20121358A1 (enExample)
PH (1) PH12012501021A1 (enExample)
PL (1) PL2505586T3 (enExample)
PT (1) PT2505586E (enExample)
RS (1) RS54910B1 (enExample)
RU (1) RU2556216C2 (enExample)
SI (1) SI2505586T1 (enExample)
SM (1) SMT201600258B (enExample)
TW (1) TWI491591B (enExample)
WO (1) WO2011065402A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
ES2983998T3 (es) * 2018-05-25 2024-10-28 Japan Tobacco Inc Compuesto de indol para tratar la cistitis intersticial
US12011448B2 (en) 2018-05-25 2024-06-18 Japan Tobacco Inc. Therapeutic or preventing agent for nephrotic syndrome including indole compound
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
MX2022007518A (es) 2019-12-20 2022-09-19 Pfizer Derivados bencimidazol.
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
CA3205020A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
JP2024517859A (ja) * 2021-05-03 2024-04-23 ニューリックス セラピューティクス,インコーポレイテッド 標的タンパク質を阻害又は分解するための化合物、それを含む組成物、それらの作製方法、及びそれらの使用方法
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
US20250002489A1 (en) * 2021-10-19 2025-01-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
WO2024213082A1 (en) * 2023-04-13 2024-10-17 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NZ545421A (en) 2003-09-08 2010-03-26 Aventis Pharma Inc Thienopyrazoles
WO2006112479A1 (ja) * 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
US20080293714A1 (en) 2005-12-20 2008-11-27 Joerg Martin Bentzien Tec Kinase Inhibitors
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
CA2651732C (en) * 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
AR079164A1 (es) 2011-12-28
JP5734628B2 (ja) 2015-06-17
PH12012501021A1 (en) 2013-01-14
MY161095A (en) 2017-04-14
EP2505586A4 (en) 2013-05-15
EP2505586B1 (en) 2016-03-02
RU2556216C2 (ru) 2015-07-10
EP2505586A1 (en) 2012-10-03
JP2020079276A (ja) 2020-05-28
US20180362506A1 (en) 2018-12-20
RS54910B1 (sr) 2016-10-31
IL220009A (en) 2017-08-31
US8299070B2 (en) 2012-10-30
EP3059234A1 (en) 2016-08-24
CA2781660C (en) 2018-06-26
SI2505586T1 (sl) 2016-08-31
PT2505586E (pt) 2016-06-03
JP2018158935A (ja) 2018-10-11
TWI491591B (zh) 2015-07-11
HK1174025A1 (en) 2013-05-31
AU2010323579A1 (en) 2012-07-19
PL2505586T3 (pl) 2016-12-30
JP2021091718A (ja) 2021-06-17
US20110306599A1 (en) 2011-12-15
DK2505586T3 (en) 2016-05-30
AU2010323579B2 (en) 2016-05-19
WO2011065402A1 (ja) 2011-06-03
US20170267662A1 (en) 2017-09-21
CY1117559T1 (el) 2017-04-26
CN102712624A (zh) 2012-10-03
CA2781660A1 (en) 2011-06-03
JP2017039761A (ja) 2017-02-23
KR101766502B1 (ko) 2017-08-08
SMT201600258B (it) 2016-08-31
JP2015172051A (ja) 2015-10-01
CO6541645A2 (es) 2012-10-16
IL220009A0 (en) 2012-07-31
BR112012012529A2 (pt) 2016-05-03
EP3766877A1 (en) 2021-01-20
ES2572935T3 (es) 2016-06-03
NZ600840A (en) 2014-01-31
US20210284627A1 (en) 2021-09-16
HUE028016T2 (en) 2016-11-28
JP2011132222A (ja) 2011-07-07
US20130116240A1 (en) 2013-05-09
US20200255408A1 (en) 2020-08-13
RU2012126129A (ru) 2013-12-27
MX2012006017A (es) 2012-06-25
CN102712624B (zh) 2014-06-04
TW201124378A (en) 2011-07-16
AU2010323579C1 (en) 2016-11-03
HRP20160579T1 (hr) 2016-07-29
ME02447B (me) 2016-09-20
KR20120096540A (ko) 2012-08-30
PE20121358A1 (es) 2012-10-23
CL2012001328A1 (es) 2012-10-05

Similar Documents

Publication Publication Date Title
BR112012012529B1 (pt) Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos
CN101723936B (zh) 激酶抑制剂及其在药学中的用途
US20050261333A1 (en) Use of and some novel imidazopyridines
CN115057855A (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
CA2627670A1 (en) Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
CN105130884B (zh) 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
CN113754580A (zh) 一种吡啶吗啉类化合物、其制备方法及其应用
CN118891039A (zh) 选择性g蛋白偶联受体激酶5抑制剂、组合物和使用方法
SK6942002A3 (en) Sulfonyl oxazole amine derivative, process for the preparation thereof, its use and pharmaceutical composition containing same
HK1174025B (en) Indole compound and pharmaceutical use thereof
CN116120322A (zh) 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途
CN120112532A (zh) Parg抑制性化合物
CN121001991A (zh) 杂环化合物及其使用方法
CN120518607A (zh) 并环类衍生物抑制剂、其制备方法和应用
HK40061853A (en) Compound useful as cdk7 kinase inhibitor and use thereof
CN120987936A (zh) 一种苯并吡唑类化合物及其制备方法和应用

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: JAPAN TOBACCO INC. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.